Privatlivspræferencer
Inderes bruger cookies for at give en bedre brugeroplevelse og en personlig service. Ved at give samtykke til brugen af cookies kan vi udvikle en endnu bedre service og vil kunne levere indhold, der er interessant for dig.
  • Forum
  • Aktiemarkeder
    • MarkederRealtidskurser, indekser og markedsudvikling
    • BørskalenderKommende resultater, noteringer og virksomhedsbegivenheder
    • UdbyttekalenderKommende og tidligere udbytter
  • Selskaber
    • SelskaberGennemse og filtrer den fulde liste over børsnoterede selskaber
    • OpdagInspiration til din næste investering
    • BørsnoteringerNye noteringer og kommende børsintroduktioner
    • Invitationer til generalforsamlingerDatoer for generalforsamlinger og aktionærinformation
  • Aktieanalyse
    • ResearchEkspertaktieanalyse og anbefalinger
    • ArtiklerNyheder, indsigter og markedskommentarer
    • inderesTVVideocenter for aktieanalyse, forskning og ekspertkommentarer
    • TransskriptionerFuldstændige udskrifter af resultatopkald og investormøder
    • AktieoversigtSammenlign nøgletal og udvikling på tværs af flere aktier
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.

Vækstaktier.dk: Scandinavian Medical Solutions lowers guidance for 2025/26

SMSMEDPressemeddelelse27.08.2026, 11.05

Scandinavian Medical Solutions yesterday lowered its guidance for the 2025/26 financial year for the second time this fiscal year.

Scandinavian Medical Solutions now expects revenue of DKK 155–175 million with a negative EBITDA of DKK 9–13 million, compared with previous guidance of revenue of DKK 190–220 million and a positive EBITDA of DKK 0–5 million. The company also lowered its guidance in April due to increased global uncertainty in its core markets. Since then, market conditions have proven more challenging than expected, and the second half of the financial year has brought continued high volatility and rising margin pressure.

Several factors are currently challenging the company: price competition has intensified further, freight costs remain elevated, and U.S. tariff rates have been maintained, keeping cost levels high. At the same time, the repayment of unlawfully collected tariffs is progressing more slowly than expected. In the Middle East in particular, several customers are awaiting clarity before making new investment decisions, while challenged global purchasing power is dampening demand across markets.

Scandinavian Medical Solutions is now launching a number of initiatives to counter these developments. The current inventory is to be gradually sold off, with the proceeds reinvested in products that better match current market conditions, offering higher turnover velocity and better margins. The company has also initiated optimizations of its capacity costs, which will only have their full effect by the half-year report for 2026/27.

CEO of Scandinavian Medical Solutions, Jens Hvid Paulsen, states:

The market has not recovered at the pace we assumed in connection with our original guidance, nor after the downward revision in April, and it is of course unsatisfactory that we must adjust our guidance again. We are therefore using the situation to change what we ourselves are in control of. By further accelerating the shift of our inventory toward products with faster turnover, we free up capital and become less dependent on exactly when the market turns.

Contacts
Email: markus@vaekstaktier.dk
Telephone: +45 50 42 99 18

About Us
Disclaimer: Vaekstaktier has a paid IR-partnership with the company mentioned. The content is for informational purposes and is a redistribution of the company’s own communications.

Website: vaekstaktier.dk

Attachments
Scandinavian Medical Solutions lowers guidance for 2025/26